Safety Profile for Healthcare Professionals

Pooled safety data from ADAPT-1 and ADAPT-2 (N=430)1*

Adverse drug reactions sorted in descending order by total patients treated with DOPTELET were: pyrexia, abdominal pain, nausea, headache, fatigue, and edema peripheral.

*ADAPT-1 and ADAPT-2 were 2 identically designed, multicenter, randomized, double-blind, placebo-controlled studies.1

†Treatment-emergent adverse reactions sorted in descending order by total patients treated with DOPTELET (N=274).1

Low discontinuation rates (<1%) due to adverse reactions

No increase in hepatotoxicity was reported in ADAPT-1 and ADAPT-22

Incidence of thrombosis (1/430): In ADAPT-1 and ADAPT-2 there was one treatment-emergent event of portal vein thrombosis

References:

1. DOPTELET [package insert]. Durham, NC: Dova Pharmaceuticals, Inc; 2018.

2. Terrault N, Chen Y-C, Izumi N, et al. Avatrombopag before procedures reduces need for platelet transfusion in patients with chronic liver disease and thrombocytopenia. Gastroenterology. 2018;155(3):705-718.